The previous suggestion that chapter 8 of the NHA is the major part of the legislation in South Africa that deals with the issue of
cell-based therapy (10) was predicated upon the recognition that this field involves several diverse but interrelated entities.
Yalung said
cell-based therapy is supported by several studies, proving it to be effective in treating and managing pain and other sports-related injuries.
In response to these issues, scientists and health professionals around the world have published comments and guidelines on what should be considered ethical and fair in
cell-based therapy. (2-7) In 2008, the International Society for Stem Cell Research published Guidelines for the Clinical Translation of Stem Cells (available at http://www.isscr.org/clinical_trans), which 'provides a framework for the responsible and timely development of clinically useful stem-cell-based therapies'.
The Specialized Centers for
Cell-Based Therapy for Heart, Lung and Blood Diseases will involve both basic and clinical research but is heavily focused on clinical applications, NHLBI said in a press release.
This additional intellectual property from The Rockefeller University expands NeoStem's comprehensive Targeted Cancer Immunotherapy Programme patent portfolio, which includes inventions relating to critical aspects of a dendritic
cell-based therapy, novel antigen-presenting cancer vaccines, stem cell growth media and methods to produce the high purity cancer initiating (stem) cells that provide the critical antigen array with which the vaccine's dendritic cells are pulsed.
Earlier the DOH released rules for the practice of stem cell and
cell-based therapy to prevent abuses and dubious practices.
Nowhere is this more apparent than in the field of
cell-based therapy, i.e.
BETHESDA, Md., January 16, 2019 -- Using a novel patient-specific stem
cell-based therapy, researchers prevented blindness in animal models of geographic atrophy, the advanced "dry" form of age-related macular degeneration (AMD), which is a leading cause of vision loss among people age 65 and older.
M2 PHARMA-March 12, 2018-JW Therapeutics Secures USD 90m Financing to Develop
Cell-based Therapy Technologies
BALTIMORE, Md., February 28, 2017 -- The first patient has been treated in the pivotal Phase 3 clinical trial of an autologous
cell-based therapy for the treatment of ischemic heart failure that develops after a heart attack.
ISTO Technologies, a privately held orthobiologics company, has completed enrolment of 44 patients for its Phase II clinical trial of NuQu, a novel,
cell-based therapy for the treatment of pain and disability associated with degenerated spinal discs.
The company acknowledges that it has little knowledge of the stem cell field, but wants to play a role in stem
cell-based therapy development.
